Luteolin inhibits angiotensin II-induced human umbilical vein endothelial cell proliferation and migration through downregulation of src and Akt phosphorylation

Circulation Journal

Volumn 77, Issue 3, 2013, Pages 772-779

  Zhu, Manyi ^a   Chen, Dan ^b   Li, Dongye ^a   Ding, Hong ^a   Zhang, Tian ^a   Xu, Tongda ^a   Zhang, Yanbin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Angiogenesis; Luteolin; Migration; Proliferation; Vascular endothelial cells

Indexed keywords

ANGIOTENSIN II; LUTEOLIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOTENSIN II; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; HUMANS; LUTEOLIN; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TIME FACTORS; UMBILICAL VEINS;

EID: 84874442882     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0310     Document Type: Article

References (35)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
2. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213-220.
3. Kyriakakis E, Cavallari M, Andert J, Philippova M, Koella C, Bochkov V, et al. Invariant natural killer T cells: Linking inflammation and neovascularization in human atherosclerosis. Eur J Immunol 2010; 40: 3268-3279.
4. Alvarez E, Rodino-Janeiro BK, Ucieda-Somoza R, González-Juanatey JR. Pravastatin counteracts angiotensin II-induced upregulation and activation of NADPH oxidase at plasma membrane of human endothelial cells. J Cardiovasc Pharmacol 2010; 55: 203-212.
5. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R. Regulation of endothelial proliferation by the rennin-angiotensin system in human umbilical vein endothelial cells. Reproduction 2008; 136: 125-130.
6. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047-1052.
7. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2006; 113: 2245-2252.
8. Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 2006; 281: 19009-19018.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
10. Valles AM, Beuvin M, Boyer B. J Biol Chem 2004; 279: 44490-44496.
11. Frame MC, Fincham VJ, Carragher NO, Wyke JA. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002; 3: 233-245.
12. Simeonova PP, Wang S, Hulderman T, Luster MI. c-Src-dependent activation of the epidermal growth factor receptor and mitogenactivated protein kinase pathway by arsenic: Role in carcinogenesis. J Biol Chem 2002; 277: 2945-2950.
13. Kyaw M, Yoshizumi M, Tsuchiya K, Kagami S, Izawa Y, Fujita Y. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1 2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol 2004; 65: 832-841.
14. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365.
15. Cicenas I. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008; 23: 1-9.
16. Persad S, Attwell S, Gray V. Regulation of protein kinase B/Aktserine 473 phosphorylation by integrin-linked kinase: Critical roles kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001; 276: 27462-27469.
17. Liao PH, Hung LM, Chen YH, Kuan YH, Zhang FB, Lin RH, et al. Cardioprotective effects of luteolin during ischemia-reperfusion injury in rats. Circ J 2011; 75: 443-450.
18. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. Biol Chem 2005; 280: 5636-5645.
19. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
20. Weber DS, Rocic P, Mellis AM, Laude K, Lyle AN, Harrison DG. Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2005; 288: 37-42.
21. Zheng Y, Song HJ, Kim CH, Kim HS, Kim EG, Sachinidis A, et al. Inhibitory effect of epigallocatechin 3-O-gallate on vascular smooth muscle cell hypertrophy induced by angiotensin I I. Cardiovasc Pharmacol 2004; 43: 200.
22. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 2000; 33: 306-310.
23. Tamarat R, Silvestre S, Durie M, Levy BI. Angiotensin II aniogenic effect in vivo involves vascular endothelial growth factor and inflammation-related pathways. Lab Invest 2002; 82: 747-756.
24. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
25. Hunt BJ. The endothelium in atherogenesis. Lupus 2009; 9: 189-193.
26. Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T. Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular system: Review and perspective. Circ J 2011; 75: 1791-1800.
27. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000; 275: 8271-8274.
28. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res 2004; 64: 7936-7946.
29. Fang F, Li D, Pan H, Chen D, Qi L, Zhang R, et al. Luteolin inhibits apoptosis and improves cardiomyocyte contractile function through the PI3K/Akt pathway in simulated ischemia/reperfusion. Pharmacology 2011; 88: 149-158.
30. Qi L, Pan H, Li D, Fang F, Chen D, Sun H. Luteolin improves contractile function and attenuates apoptosis following ischemia-reperfusion in adult rat cardiomyocytes. Eur J Pharmacol 2011; 668: 201-207.
31. Gorenne I, Kavurma M, Scott S, Bennett M. Vascular smooth muscle cell senescence in atherosclerosis. Cardiovasc Res 2006; 72: 9-17.
32. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 812-819.
33. López-Lázaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 2009; 9: 31-59.
34. Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation 2010; 7: 3.
35. Fotsis T, Pepper MS, Aktas E, Breit S, Adlercreutz K, Montesano R. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997; 57: 2916-2921.